Recent Updates
Recently added Catalysts
VNDA

Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders

Key Takeaway: WASHINGTON, May 31, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will hold its 2012 A

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+121%
120-day peak, hindsight
Typical move
19.9%
average across 7 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
Imsidolimab
Phase 2 · Palmoplantar Pustulosis

Full Press Release Details

WASHINGTON, May 31, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will hold its 2012 Annual Meeting of Stockholders on Thursday, June 14, 2012, in Washington, D.C. The record date for the Annual Meeting is April 20, 2012. Only stockholders of record as of the close of business on April 20, 2012 may vote at the meeting or any adjournment thereof. Vanda's proxy statement and annual report are available at www.proxyvote.com and includes the time and location of the Annual Meeting, as well as a description of the matters to be considered.
ABOUT VANDA PHARMACEUTICALS INC.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.
Senior Communications Manager
Vanda Pharmaceuticals Inc.
Last updated: May 31, 2012